Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
Kerbrat
P
P
Centre Eugène Marquis, CHU Pontchaillou, Rennes, France.
Somers
R
R
Verweij
J
J
Crowther
D
D
Tursz
T
T
Santoro
A
A
Steward
W P
WP
Lentz
M A
MA
van Glabbeke
M
M
Mouridsen
H T
HT
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine